The dual S1PR1/S1PR5 drug BAF312 (Siponimod) attenuates demyelination in organotypic slice cultures

BACKGROUND: BAF312 (Siponimod) is a dual agonist at the sphingosine-1 phosphate receptors, S1PR1 and S1PR5. This drug is currently undergoing clinical trials for the treatment of secondary progressive multiple sclerosis (MS). Here, we investigated the effects of BAF312 on isolated astrocyte and micr...

Descripción completa

Detalles Bibliográficos
Autores principales: O’Sullivan, Catherine, Schubart, Anna, Mir, Anis K., Dev, Kumlesh K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4746808/
https://www.ncbi.nlm.nih.gov/pubmed/26856814
http://dx.doi.org/10.1186/s12974-016-0494-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4746808/
https://www.ncbi.nlm.nih.gov/pubmed/26856814
http://dx.doi.org/10.1186/s12974-016-0494-x

Ejemplares similares